Skip to content

Veracyte VCYT Additional Paid-In Capital

Additional Paid-In Capital at other companies

Guardant Health logo
Guardant HealthGH
$2.93B+18.5%
Natera, Inc. logo
Natera, Inc.NTRA
$4.64B+19.6%
Bio-Rad Laboratories logo
Bio-Rad LaboratoriesBIO
$490.5M+3.1%
Revvity logo
RevvityRVTY
$1.24B-36.7%
Labcorp Holdings logo
Labcorp HoldingsLH
$0-100%
Quest Diagnostics logo
Quest DiagnosticsDGX
$2.35B+1.6%

Other financials

Income statement

See full
Revenue$139.1M+21.5%
Gross profit$101.2M+27.2%
Operating income$22.6M+680%
Net income$28.7M+307%
EPS (diluted)$0.35+289%

Balance sheet

See full
Cash & equivalents$264.8M+41.0%
Total debt$39.3M-22.1%
Total equity$1.3B+12.5%
Total assets$1.4B+9.2%

Cash flow

See full
Operating cash flow$35.2M+557%
CapEx$3.0M+62.8%
Free cash flow$32.3M+810%

Valuation

See full
Market cap$4.29B+10.7%

Profitability

See full
Gross margin70.9%+2.9pp
Operating margin14.3%+9.2pp
Net margin16.2%+9.1pp
FCF margin28.7%+11.7pp

Returns & leverage

See full
Return on equity6.9%+4.1pp
Debt / equity0.0×
Current ratio9.3×+4.2×

Where this comes from

Reported directly by Veracyte in its filing.

Tagged under the XBRL concept us-gaap:AdditionalPaidInCapitalCommonStock.

The official record: Veracyte’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Veracyte's additional paid-in capital.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Veracyte's additional paid-in capital?
Veracyte (VCYT) reported additional paid-in capital of $1.7B in Q1 2026.
How has Veracyte's additional paid-in capital changed year-over-year?
Veracyte's additional paid-in capital increased by 2.5% year-over-year, from $1.66B to $1.7B.
What is the long-term trend for Veracyte's additional paid-in capital?
Over 5 years (2020 to 2025), Veracyte's additional paid-in capital has grown at a 19.3% compound annual growth rate (CAGR), from $702.77M to $1.7B.
What does additional paid-in capital mean?
Capital received from shareholders in excess of par value — the premium investors paid over the nominal value of shares at issuance, plus stock-based compensation effects.